Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Hankey, GJ; Ford, AH; Yi, Q; Eikelboom, JW; Lees, KR; Chen, C; Xavier, D; Navarro, JC; Ranawaka, UK; Uddin, W; Ricci, S; Gommans, J; Schmidt, R; Almeida, OP; van Bockxmeer, FM; on Behalf of the VITATOPS Trial Study Group.
Effect of B-Vitamins and Lowering Homocysteine on Cognitive Impairment in Patients With Previous Stroke or Transient Ischemic Attack: A Prespecified Secondary Analysis of a Randomized, Placebo-Controlled Trial and Meta-Analysis.
Stroke. 2013; 44(8):2232-2239 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Schmidt Reinhold

Dimensions Citations:

Plum Analytics:
Background and Purpose High plasma total homocysteine (tHcy) has been associated with cognitive impairment but lowering tHcy with B-vitamins has produced equivocal results. We aimed to determine whether B-vitamin supplementation would reduce tHcy and the incidence of new cognitive impairment among individuals with stroke or transient ischemic attack 6 months previously. Methods A total of 8164 patients with stroke or transient ischemic attack were randomly allocated to double-blind treatment with one tablet daily of B-vitamins (folic acid, 2 mg; vitamin B6, 25 mg; vitamin B12, 500 g) or placebo and followed up for 3.4 years (median) in the VITAmins TO Prevent Stroke (VITATOPS) trial. For this prespecified secondary analysis of VITATOPS, the primary outcome was a new diagnosis of cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score <24 on 2 follow-up visits. Secondary outcomes were cognitive decline, and the mean tHcy and MMSE at final follow-up. Results A total of 3089 participants (38%) voluntarily undertook the MMSE >6 months after the qualifying stroke; 2608 participants were cognitively unimpaired (MMSE 24), of whom 2214 participants (1110 B-vitamins versus 1104 placebo) had follow-up MMSEs during 2.8 years (median). At final follow-up, allocation to B-vitamins, compared with placebo, was associated with a reduction in mean tHcy (10.2 mol/L versus 14.2 mol/L; P<0.001) but no change from baseline in the mean MMSE score (-0.22 points versus -0.25 points; difference, 0.03; 95% confidence interval, -0.13 to 0.19; P=0.726) and no difference in the incidence of cognitive impairment (5.51% versus 5.47%; risk ratio, 1.01; 95% confidence interval, 0.69-1.48; P=0.976), cognitive decline (9.1% versus 10.3%; risk ratio, 0.89; 0.67-1.18; P=0.414), or cognitive impairment or decline (11.0% versus 11.3%; risk ratio, 0.98; 0.75-1.27; P=0.855). Conclusions Daily supplementation with folic acid, vitamin B6, and vitamin B12 to a self-selected clinical trial cohort of cognitively unimpaired patients with previous stroke or transient ischemic attack lowered mean tHcy but had no effect on the incidence of cognitive impairment or cognitive decline, as measured by the MMSE, during a median of 2.8 years. Clinical Trial Registration URL: Unique identifier: ISRCTN74743444; URL: Unique identifier: NCT00097669.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Cognition Disorders - drug therapy Cognition Disorders - etiology Cognition Disorders - prevention & control
Double-Blind Method -
Female -
Follow-Up Studies -
Homocysteine - antagonists & inhibitors Homocysteine - blood
Humans -
Ischemic Attack, Transient - complications Ischemic Attack, Transient - drug therapy
Male -
Middle Aged -
Placebos -
Recurrence -
Stroke - complications Stroke - drug therapy
Treatment Outcome -
Vitamin B 12 - administration & dosage Vitamin B 12 - physiology
Vitamin B Complex - administration & dosage Vitamin B Complex - pharmacology

Find related publications in this database (Keywords)
clinical trial
cognitive impairment
vitamin B complex
© Meduni Graz Impressum